{"id":6671,"date":"2024-11-21T16:01:35","date_gmt":"2024-11-21T15:01:35","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6671"},"modified":"2025-04-28T21:30:22","modified_gmt":"2025-04-28T19:30:22","slug":"zanubrutinib-alone-and-in-combination-with-tislelizumab-for-the-treatment-of-richter-transformation-of-chronic-lymphocytic-leukemia-2","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/zanubrutinib-alone-and-in-combination-with-tislelizumab-for-the-treatment-of-richter-transformation-of-chronic-lymphocytic-leukemia-2\/","title":{"rendered":"Zanubrutinib, alone and in combination with tislelizumab, for the treatment of Richter transformation of chronic lymphocytic leukemia\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6671","publication","type-publication","status-publish","hentry","disease_state-chronic-lymphocytic-leukemia","molecule-zanubrutinib"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6671","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6671"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6671"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}